Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 4/2011

01-12-2011 | Research

High Frequency of Genes’ Promoter Methylation, but Lack of BRAF V600E Mutation among Iranian Colorectal Cancer Patients

Authors: Fakhraddin Naghibalhossaini, Hamideh Mahmoodzadeh Hosseini, Pooneh Mokarram, Mozhdeh Zamani

Published in: Pathology & Oncology Research | Issue 4/2011

Login to get access

Abstract

Gene silencing due to DNA hypermethylation is a major mechanism for loss of tumor suppressor genes function in colorectal cancer. Activating V600E mutation in BRAF gene has been linked with widespread methylation of CpG islands in sporadic colorectal cancers. The aim of the present study was to evaluate the methylation status of three cancer-related genes, APC2, p14ARF, and ECAD in colorectal carcinogenesis and their association with the mutational status of BRAF and KRAS among Iranian colorectal cancer patients. DNA from 110 unselected series of sporadic colorectal cancer patients was examined for BRAF V600E mutation by PCR-RFLP. Promoter methylation of genes in tumors was determined by methylation specific PCR. The frequency of APC2, E-CAD, and p14 methylation was 92.6%, 40.4% and 16.7%, respectively. But, no V600E mutation was identified in the BRAF gene in any sample. No association was found in cases showing epigenetic APC, ECAD, and p14 abnormality with the clinicopathological parameters under study. The association between KRAS mutations and the so called methylator phenotype was previously reported. Therefore, we also analyzed the association between the hot spot KRAS gene mutations in codons of 12 and 13 with genes’ promoter hypermethylation in a subset of this group of patients. Out of 86 tumors, KRAS was mutated in 24 (28%) of tumors, the majority occurring in codon 12. KRAS mutations were not associated with genes’ methylation in this tumor series. These findings suggest a distinct molecular pathway for methylation of APC2, p14, and ECAD genes from those previously described for colorectal cancers with BRAF or KRAS mutations.
Literature
1.
Malekzadeh R, Bishehsari F, Mahdavinia M, Ansari R (2009) Epidemiology and molecular genetics of colorectal cancer in Iran: a review. Arch Iran Med 12:161–169PubMed
2.
Fazeli MS, Adel MG, Lebaschi AH (2007) Colorectal carcinoma: a retrospective, descriptive study of age, gender, subsite, stage, and differentiation in Iran from 1995 to 2001 as observed in Tehran University. Dis Colon Rectum 50:990–995PubMedCrossRef
3.
Jass JR (2007) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50:113e30
4.
Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP (1999) CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96:8681–8686PubMedCrossRef
5.
Marais R, Marshall CJ (1996) Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv 27:101–125PubMed
6.
Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B (2006) BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 5:2PubMedCrossRef
7.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954PubMedCrossRef
8.
Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418:934PubMedCrossRef
9.
Suehiro Y, Wong CW, Chirieac LR, Kondo Y, Shen L, Webb CR et al (2008) Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res 14:2560–2569PubMedCrossRef
10.
Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA et al (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38:787–793PubMedCrossRef
11.
English DR, Young JP, Simpson JA, Jenkins MA, Southey MC, Walsh MD et al (2008) Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomark Prev 17:1774–1780CrossRef
12.
Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, Kimura K et al (2004) Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 22:4584–4594PubMedCrossRef
13.
Kominami K, Nagasaka T, Cullings HM, Hoshizima N, Sasamoto H, Young J et al (2009) Methylation in p14(ARF) is frequently observed in colorectal cancer with low-level microsatellite instability. J Int Med Res 37:1038–1045PubMed
14.
Auerkari EI (2006) Methylation of tumor suppressor genes p16 (INK4a), p27(Kip1) and E-cadherin in carcinogenesis. Oral Oncol 42:5–13PubMedCrossRef
15.
Schuebel KE, Chen W, Cope L, Glöckner SC, Suzuki H, Yi JM et al (2007) Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 3:1709–1723PubMedCrossRef
16.
Kumar K, Brim H, Giardiello F, Smoot DT, Nouraie M, Lee EL et al (2009) Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. Clin Cancer Res 15:1155–1161PubMedCrossRef
17.
Garinis GA, Menounos PG, Spanakis NE, Papadopoulos K, Karavitis G, Parassi I et al (2002) Hypermethylation-associated transcriptional silencing of E-cadherin in primary sporadic colorectal carcinomas. J Pathol 198:442–449PubMedCrossRef
18.
19.
Zheng S, Chen P, McMillan A, Lafuente A, Lafuente MJ, Ballesta A et al (2000) Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors. Carcinogenesis 21:2057–2064PubMedCrossRef
20.
Mokarram P, Naghibalhossaini F, Saberi Firoozi M, Hosseini SV, Izadpanah A, Salahi H et al (2008) Methylenetetrahydrofolate reductase C677T genotype affects promoter methylation of tumor-specific genes in sporadic colorectal cancer through an interaction with folate/vitamin B12 status. World J Gastroenterol 14:3662–3671PubMedCrossRef
21.
Servomaa K, Kiuru A, Kosma VM, Hirvikoski P, Rytömaa T (2000) p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women. Mol Pathol 53:24–30PubMedCrossRef
22.
Gazin C, Wajapeyee N, Gobeil S, Virbasius CM, Green MR (2007) An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 449:1073–1077PubMedCrossRef
23.
Mokarram P, Kumar K, Brim H, Naghibalhossaini F, Saberi-firoozi M, Nouraie M et al (2009) Distinct high-profile methylated genes in colorectal cancer. PLoS ONE 4:e7012PubMedCrossRef
24.
Miranda E, Destro A, Malesci A, Balladore E, Bianchi P, Baryshnikova E et al (2006) Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. Br J Cancer 95:1101–1107PubMedCrossRef
25.
Wheeler JM, Kim HC, Efstathiou JA, Ilyas M, Mortensen NJ, Bodmer WF (2001) Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer. Gut 48:367–371PubMedCrossRef
26.
Strathdee G (2002) Epigenetic versus genetic alterations in the inactivation of E-cadherin. Semin Cancer Biol 12:373–379PubMedCrossRef
27.
van Engeland M, Weijenberg MP, Roemen GM, Brink M, de Bruïne AP, Goldbohm RA et al (2003) Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res 63:3133–3137PubMed
28.
Naghibalhossaini F, Mokarram P, Khalili I, Vasei M, Hosseini SV, Ashktorab H et al (2010) MTHFR C677T and A1298C variant genotypes and the risk of microsatellite instability among Iranian colorectal cancer patients. Cancer Genet Cytogenet 197:142–151PubMedCrossRef
29.
Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C et al (2002) Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62:6451–6455PubMed
30.
Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS (2007) Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 9:305–314PubMedCrossRef
31.
Brim H, Mokarram P, Naghibalhossaini F, Saberi-Firoozi M, Al-Mandhari M, Al-Mawaly K et al (2008) Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer 7:68PubMedCrossRef
Metadata
Title
High Frequency of Genes’ Promoter Methylation, but Lack of BRAF V600E Mutation among Iranian Colorectal Cancer Patients
Authors
Fakhraddin Naghibalhossaini
Hamideh Mahmoodzadeh Hosseini
Pooneh Mokarram
Mozhdeh Zamani
Publication date
01-12-2011
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 4/2011
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-011-9388-5

Other articles of this Issue 4/2011

Pathology & Oncology Research 4/2011 Go to the issue

Research

Prognostic Significance of Wnt-1, β-catenin and E-cadherin Expression in Advanced Colorectal Carcinoma

Review

Roles of Hormones and Signaling Molecules in Describing the Relationship Between Obesity and Colon cancer

Research

Breast Tumor Characteristics in Hormone Replacement Therapy Users

Case Report

Invasion of the Hypoglossal Nerve by Adenoid Cystic Carcinoma of the Tongue: Case Report and Review of the Literature

Research

Classical and Alternative Nuclear Factor-κB Pathways: A Comparison among Normal Prostate, Benign Prostate Hyperplasia and Prostate Cancer

Research

Stem Cell Associated Genes Working with One MiRNA Cluster Have Different Clinic Pathologic Values in Gastric Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits